Internal Medicine, Clinical Cardiatric Electrophysiology · Glendale, CA
NPI
1558447607
Since 2006
Specialty
Internal Medicine, Clinical Cardiatric Electrophysiology
Code 207RC0001X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1251 S Glendale Ave
Glendale, CA, 91205
Phone (818) 500-9393
Groups this clinician bills Medicare through
Medicare paid, 2024
$356K
7,103 services
Medicare patients, 2024
778
Average age 76
Drug cost, 2024
$11.0M
80,155 prescriptions
Company payments, 2025
$1,687
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tsovinar Tekkelian was code 99214 (office e&m - established), 1,325 times for 591 patients. In total Tsovinar Tekkelian billed 7,103 services in 29 codes, and Medicare paid $356K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,325 | 591 | $104.53 | $139K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,263 | 531 | $52.99 | $67K |
| 99213 Office E&M - Established | Office | 825 | 469 | $71.98 | $59K |
| 82962 Clinical Chemistry | Office | 791 | 267 | $3.21 | $2,539 |
| 36415 Venipuncture Blood Collection | Office | 702 | 495 | $8.65 | $6,072 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 671 | 128 | $0.74 | $494 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 347 | 347 | $21.09 | $7,318 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 315 | 315 | $140.22 | $44K |
| 96372 Injection Administration | Office | 228 | 160 | $11.81 | $2,692 |
| G0447 Face-to-face behavioral counseling for obesity, 15 minutes | Office | 145 | 145 | $26.80 | $3,887 |
| 99212 Office E&M - Established | Office | 111 | 91 | $48.56 | $5,390 |
| 93000 Electrocardiogram | Office | 82 | 77 | $11.82 | $969 |
| 94640 Treatment - Miscellaneous | Office | 73 | 49 | $6.92 | $505 |
| 99204 Office E&M - New | Office | 50 | 50 | $117.62 | $5,881 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 33 | 32 | $242.84 | $8,014 |
By year: 2022 $328K for 6,400 services; 2023 $264K for 5,458 services; 2024 $356K for 7,103 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 791 | 267 | $3.21 | $2,539 |
| 36415 Venipuncture Blood Collection | 702 | 495 | $8.65 | $6,072 |
Medicare prescription drug claims, 2024
In 2024, the drug Tsovinar Tekkelian prescribed most often to Medicare patients was Rosuvastatin Calcium, with 3,923 prescriptions and refills. In total Tsovinar Tekkelian wrote 80,155 Medicare prescriptions that cost $11.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 3,923 | 4,830 | 510 | $23K |
| Gabapentin Generic | 3,336 | 3,603 | 406 | $9,218 |
| Metoprolol Succinate Generic | 2,501 | 3,066 | 323 | $20K |
| Amlodipine Besylate Generic | 1,969 | 2,409 | 257 | $3,833 |
| Escitalopram Oxalate Generic | 1,679 | 1,939 | 205 | $5,047 |
| Vascepa Icosapent Ethyl | 1,547 | 1,658 | 210 | $410K |
| Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide | 1,438 | 1,829 | 198 | $28K |
| Levothyroxine Sodium Generic | 1,362 | 1,803 | 160 | $8,512 |
| Clonidine Hcl Generic | 1,303 | 1,329 | 167 | $5,704 |
| Hydralazine Hcl Generic | 1,260 | 1,363 | 149 | $5,487 |
| Furosemide Generic | 1,237 | 1,344 | 161 | $2,112 |
| Baclofen Generic | 1,200 | 1,285 | 163 | $4,013 |
| Diclofenac Sodium Generic | 1,138 | 1,180 | 194 | $471K |
| Omeprazole Generic | 1,048 | 1,191 | 151 | $2,908 |
| Ibuprofen Generic | 1,048 | 1,075 | 176 | $7,925 |
Brand drugs: 13,000 claims; generic drugs: 65,889 claims; opioid claims: 1,054.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tsovinar Tekkelian $1,687 ($1,687 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $228.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 9 | $228 |
| Ardelyx, Inc. ARDX | 8 | $227 |
| Amgen Inc. AMGN | 8 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 4 | $122 |
| Aimmune Therapeutics, Inc. | 4 | $114 |
| Novo Nordisk Inc NVO | 5 | $105 |
| Lundbeck LLC | 4 | $101 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $93.35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62.92 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $62.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.